[144] PTC Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

PTC Therapeutics Form 144 filing notifies a proposed sale of 39,850 common shares through Fidelity Brokerage Services with an aggregate market value of $2,268,373.83, intended for sale on 09/08/2025 on NASDAQ. The filing lists four lots acquired via stock options granted in 2016, 2017 and 2018 and shows cash payment on the stated sale date. The filing states there were no securities sold by the reporting person in the prior three months and includes the required attestation that the seller does not possess undisclosed material information. The notice follows Rule 144 disclosure requirements.

Positive

• Clear disclosure of broker, exchange, share count and aggregate market value
• Breakdown of acquisition lots showing options granted and dates for provenance
• Seller attestation that no undisclosed material information is held

Negative

• Insider sale of shares may be viewed negatively by some investors despite limited size
• No 10b5-1 plan date is indicated in the form, which could raise questions about trading pre-commitment

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure of ~39.9k shares totaling $2.27M; standard Rule 144 reporting, limited market impact.

The filing documents a proposed sale of 39,850 common shares via Fidelity with an aggregate market value of $2,268,373.83, sourced from options granted in 2016–2018 and to be paid in cash. No sales in the prior three months are reported, and the seller certifies absence of undisclosed material information. For investors this is a routine liquidity event rather than a corporate action; it provides transparency on insider selling but contains no financial performance metrics or new corporate developments.

Corporate Governance Expert

TL;DR: Disclosure aligns with compliance norms; attestation and option provenance increase governance transparency.

The notice identifies the securities as option-originated shares with acquisition dates and quantities, and specifies the broker and exchange. The inclusion of the seller's representation about material information and the absence of prior three-month sales are consistent with good disclosure practice under Rule 144. The filing does not indicate any 10b5-1 plan adoption date or special instructions, and contains no governance concerns beyond a standard insider sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	39850	2268373.83	79438094	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2025	Option Granted - 01/03/2017	Issuer			8423	09/08/2025	Cash
Common	09/08/2025	Option Granted - 01/04/2016	Issuer			20411	09/08/2025	Cash
Common	09/08/2025	Option Granted - 01/03/2018	Issuer			8528	09/08/2025	Cash
Common	09/08/2025	Option Granted - 02/25/2016	Issuer			2488	09/08/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for PTC Therapeutics (PTCT) report?

The filing reports a proposed sale of 39,850 common shares through Fidelity with an aggregate market value of $2,268,373.83 to be sold on 09/08/2025 on NASDAQ.

What is the source of the shares being sold in the PTCT Form 144?

All shares listed were acquired via stock options granted in 2016, 2017, and 2018, with specific lot sizes shown in the filing.

Did the filer report any sales of issuer securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the reporting person.

Who is the broker handling the proposed sale in the Form 144?

The broker named is Fidelity Brokerage Services LLC located at the address shown in the filing.

Does the filing include an attestation about material information?

Yes, the reporting person represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.